IRLAB receives approval to initiate Phase II trials with IRL752
IRLAB has received approval from Läkemedelsverket (the Swedish MPA) and Regionala Etikprövningsnämnden, EPN, (the Ethics committee, Stockholm) to conduct a Phase II clinical trial with IRL752. IRL752 is a cortical enhancer designed to treat Parkinsons disease dementia.“The approval from the MPA and the ethics committee is very encouraging. The Phase II study with IRL752 is a double-blind placebo controlled study in patients with Parkinson’s disease and dementia. About 80 % of all patients suffering from Parkinson’s disease develops symptoms of dementia which, today, lack satisfactory